ArticleMolecular therapy. Nucleic acids2012
A Hyperactive Transposase Promotes Persistent Gene Transfer of a piggyBac DNA Transposon.
Article in Molecular therapy. Nucleic acids, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 51 citations in OpenAlex.
- Charcot-Marie-Tooth disease type 1E: clinical natural history and molecular impact of PMP22 variants.Brain : a journal of neurology · 2026Article
- MultiSite Assembly of Gateway Induced Clones (MAGIC): a flexible cloning toolbox for use in vertebrate model systems.Development (Cambridge, England) · 2025Article
- Random Insertion Reporter Gimmicks Powered by Cut-and-Paste DNA Transposons.Biomedicines · 2025Review
- Charcot-Marie-Tooth disease type 1E: Clinical Natural History and Molecular Impact ofmedRxiv : the preprint server for health sciences · 2025Article
- High-throughput functional screen identifies YWHAZ as a key regulator of pancreatic cancer metastasis.Cell death & disease · 2023Article
- A mammalian cell display platform based on scFab transposition.Antibody therapeutics · 2023Article
- Transposase N-terminal phosphorylation and asymmetric transposon ends inhibit piggyBac transposition in mammalian cells.Nucleic acids research · 2022Article
- Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs.Molecular therapy. Nucleic acids · 2022Article
- Progress of Transposon Vector System for Production of Recombinant Therapeutic Proteins in Mammalian Cells.Frontiers in bioengineering and biotechnology · 2022Review
- Proof of principle for piggyBac-mediated transgenesis in the flatworm Macrostomum lignano.Genetics · 2021Article
- In Situ Programming of CAR T Cells.Annual review of biomedical engineering · 2021Review
- Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease.Human gene therapy · 2020Review
- Structural basis of seamless excision and specific targeting by piggyBac transposase.Nature communications · 2020Article
- Transposon vector-mediated stable gene transfer for the accelerated establishment of recombinant mammalian cell pools allowing for high-yield production of biologics.Biotechnology letters · 2020Review
- In VivoInternational journal of molecular sciences · 2019Article
- Review
- Genetic Engineering of Human Pluripotent Stem Cells Using PiggyBac Transposon System.Current protocols in stem cell biology · 2018Article
- Article
- Comparative analysis of chimeric ZFP-, TALE- and Cas9-piggyBac transposases for integration into a single locus in human cells.Nucleic acids research · 2017Article
- In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers.Nature nanotechnology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Nonviral vector systems are used increasingly in gene targeting and gene transfer applications. The piggyBac transposon represents an alternative integrating vector for in vivo gene transfer. We hypothesized that this system could achieve persistent gene transfer to the liver when administered systemically. We report that a novel hyperactive transposase generated higher transposition efficiency than a codon-optimized transposase in a human liver cell line. Hyperactive transposase-mediated reporter gene expression persisted at levels twice that of codon-optimized transposase in the livers of mice for the 6-month study. Of note, expression persisted in mice following partial hepatectomy, consistent with expression from an integrated transgene. We also used the hyperactive transposase to deliver the human α(1)-antitrypsin gene and achieved stable expression in serum. To determine the integration pattern of insertions, we performed large-scale mapping in human cells and recovered 60,685 unique hyperactive transposase-mediated insertions. We found that a hyperactive piggyBac transposase conferred an altered pattern of integration from that of insect piggyBac transposase, with a decreased frequency of integration near transcription start sites than previously reported. Our results support that the piggyBac transposon combined with the hyperactive transposase is an efficient integrating vector system for in vitro and in vivo applications.Molecular Therapy - Nucleic Acids (2012) 1, e50; doi:10.1038/mtna.2012.12; published online 16 October 2012.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.